[시장보고서]세계의 치료용 BCG 백신 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 유형별(면역BCG, 치료BCG), 인구 동태별(성인, 소아과), 최종 사용자별(진료소, 병원), 지역별, 경쟁별(2020-2030년)

세계의 치료용 BCG 백신 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 유형별(면역BCG, 치료BCG), 인구 동태별(성인, 소아과), 최종 사용자별(진료소, 병원), 지역별, 경쟁별(2020-2030년)

Therapeutic BCG Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Type (Immune BCG, Therapy BCG), by Demographics (Adults, Pediatrics), by End User (Clinics, Hospitals), By Region and Competition, 2020-2030F

상품코드 : 1728365

리서치사 : TechSci Research

발행일 : 2025년 05월

페이지 정보 : 영문 180 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,508,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,954,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,570,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 치료용 BCG 백신 시장은 2024년에 6,029만 달러로 평가되었고, 예측 기간 동안 CAGR 3.86%로 성장할 전망이며, 2030년에는 7,568만 달러에 이를 것으로 예측됩니다.

BCG 백신(Bacillus Calmette-Guerin)은 현재 결핵 예방 백신으로 유일하게 승인되고 있습니다. 일반적으로 결핵 유행국에서는 출생시에, 저발생 지역에서는 위험이 높은 유아에 접종되며, 주로 폐를 침범하지만 다른 장기로 전이할 가능성이 있는 결핵의 예방에 도움이 되고 있습니다. BCG는 그 유효성 때문에 국가의 예방 접종 일정에도 포함되어 있습니다. 결핵뿐만 아니라 BCG 백신의 치료 용도는 현재 진행 중인 조사에 따라 방광암, 자가면역질환, 각종 암 등의 질환으로도 확산되고 있습니다. 이와 같이 치료 범위가 넓어지고 있는 것에 가세해 안전성과 이용 편리성이 확립되고 있는 것이, 시장의 꾸준한 성장을 지탱하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모(2024년)	6,029만 달러
시장 규모(2030년)	7,568만 달러
CAGR(2025-2030년)	3.86%
급성장 부문	면역 BCG 부문
최대 시장	북미

시장 성장 촉진요인

생명 공학의 진보

주요 시장 과제

백신 부족

주요 시장 동향

결핵 치료 및 예방

영문목차

The Global Therapeutic BCG Vaccine Market was valued at USD 60.29 Million in 2024 and is projected to reach USD 75.68 Million by 2030, growing at a CAGR of 3.86% during the forecast period. The BCG vaccine (Bacillus Calmette-Guerin) remains the only approved vaccine for tuberculosis (TB) prevention. Typically administered at birth in TB-endemic countries, and to high-risk infants in low-incidence regions, it helps prevent TB, which primarily affects the lungs but may spread to other organs. BCG is also incorporated in national immunization schedules due to its effectiveness. Beyond TB, therapeutic applications of the BCG vaccine are expanding to include diseases like bladder cancer, autoimmune disorders, and various cancers, driven by ongoing research. This broader therapeutic scope, along with its established safety and accessibility, continues to support steady growth in the market.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 60.29 Million
Market Size 2030	USD 75.68 Million
CAGR 2025-2030	3.86%
Fastest Growing Segment	Immune BCG Segment
Largest Market	North America

Key Market Drivers

Biotechnology Advancements

Biotechnology advancements involve innovations in utilizing biological systems and organisms to develop new technologies and products that improve human health and other sectors. In healthcare, progress in genetic engineering-such as the use of CRISPR-Cas9-has enabled precise gene editing, leading to breakthroughs in vaccine development, including therapeutic BCG vaccines. Additionally, the rise of biopharmaceuticals such as monoclonal antibodies and gene therapies is reshaping treatment approaches. Personalized medicine, driven by human genome sequencing and advanced genomics, is also emerging, enabling more targeted and effective treatments. Stem cell research continues to offer promise in regenerative medicine and organ repair. Synthetic biology further supports the creation of engineered organisms for practical uses in health, industry, and the environment. Together, these advancements enhance the development and application of therapeutic BCG vaccines across various disease areas.

Key Market Challenges

Vaccine Shortages

Producing BCG vaccines is a sensitive and intricate process, requiring controlled conditions to culture live bacteria. Any disruption-such as contamination or quality issues-can significantly hamper production. The global supply is dependent on a limited number of manufacturers, making the market susceptible to disruptions if one producer faces setbacks. Strict regulatory and quality control standards, although necessary, can delay production or cause batch rejections. Variability in demand due to disease trends or clinical trial requirements adds to the difficulty in maintaining consistent supply. Furthermore, imbalances in regional distribution and unexpected spikes in demand, such as during outbreaks or new therapeutic applications, can quickly deplete stockpiles and exacerbate shortages.

Key Market Trends

Tuberculosis (TB) Treatment and Prevention

The BCG vaccine has long been used to prevent tuberculosis, especially in areas with a high disease burden, by reducing the risk of infection and severe forms of TB in children. Beyond prevention, BCG is used in immunotherapy to treat non-muscle-invasive bladder cancer (NMIBC), where it activates the immune system to target cancer cells. Research is expanding into new therapeutic areas, exploring its potential in autoimmune diseases, infectious diseases, and other types of cancer. The emergence of drug-resistant TB strains, such as MDR-TB and XDR-TB, has further heightened the relevance of BCG vaccines, prompting investigations into their use as complementary treatments in drug-resistant TB management.

Key Market Players

Merck & Co., Inc.
Sanofi Pasteur Inc.
Japan BCG Laboratory
China National Biotec Group
Serum Institute of India Pvt. Ltd,
InterVax Ltd
GreenSignal Bio Pharma Limited
Statens Serum Institute
PowderJect Pharmaceuticals
Biomed Lublin

Report Scope:

In this report, the Global Therapeutic BCG Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Therapeutic BCG Vaccine Market, By Type:

Immune BCG
Therapy BCG

Therapeutic BCG Vaccine Market, By End User:

Clinics
Hospitals

Therapeutic BCG Vaccine Market, By region:

North America
- United States
- Canada
- Mexico
Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic BCG Vaccine Market.

Available Customizations:

Global Therapeutic BCG Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutic BCG Vaccine Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Immune BCG, Therapy BCG)
- 5.2.2. By End User (Clinics, Hospitals)
- 5.2.3. By Country
- 5.2.4. By Company (2024)
5.3. Market Map

6. Asia Pacific Therapeutic BCG Vaccine Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By End User
- 6.2.3. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Therapeutic BCG Vaccine Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By End User
- 6.3.2. India Therapeutic BCG Vaccine Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By End User
- 6.3.3. Australia Therapeutic BCG Vaccine Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By End User
- 6.3.4. Japan Therapeutic BCG Vaccine Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Type
    - 6.3.4.2.2. By End User
- 6.3.5. South Korea Therapeutic BCG Vaccine Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Type
    - 6.3.5.2.2. By End User

7. Europe Therapeutic BCG Vaccine Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By End User
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Therapeutic BCG Vaccine Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By End User
- 7.3.2. Germany Therapeutic BCG Vaccine Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By End User
- 7.3.3. Spain Therapeutic BCG Vaccine Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By End User
- 7.3.4. Italy Therapeutic BCG Vaccine Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By End User
- 7.3.5. United Kingdom Therapeutic BCG Vaccine Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By End User

8. North America Therapeutic BCG Vaccine Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By End User
- 8.2.3. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Therapeutic BCG Vaccine Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By End User
- 8.3.2. Mexico Therapeutic BCG Vaccine Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By End User
- 8.3.3. Canada Therapeutic BCG Vaccine Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By End User

9. South America Therapeutic BCG Vaccine Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By End User
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Therapeutic BCG Vaccine Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By End User
- 9.3.2. Argentina Therapeutic BCG Vaccine Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By End User
- 9.3.3. Colombia Therapeutic BCG Vaccine Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By End User

10. Middle East and Africa Therapeutic BCG Vaccine Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By End User
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Therapeutic BCG Vaccine Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By End User
- 10.3.2. Saudi Arabia Therapeutic BCG Vaccine Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By End User
- 10.3.3. UAE Therapeutic BCG Vaccine Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Therapeutic BCG Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1. Merck & Co., Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. Sanofi Pasteur Inc.
16.3. Japan BCG Laboratory
16.4. China National Biotec Group
16.5. Serum Institute of India Pvt. Ltd,
16.6. InterVax Ltd
16.7. GreenSignal Bio Pharma Limited
16.8. Statens Serum Institute
16.9. PowderJect Pharmaceuticals Ltd.
16.10.Biomed Lublin

한글목차

시장 성장 촉진요인

주요 시장 과제

주요 시장 동향

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 치료용 BCG 백신 시장 전망

제6장 아시아태평양의 치료용 BCG 백신 시장 전망

제7장 유럽의 치료용 BCG 백신 시장 전망

제8장 북미의 치료용 BCG 백신 시장 전망

제9장 남미의 치료용 BCG 백신 시장 전망

제10장 중동 및 아프리카의 치료용 BCG 백신 시장 전망

제11장 시장 역학

제12장 시장 동향 및 발전

제13장 세계의 치료용 BCG 백신 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

제15장 PESTEL 분석

제16장 경쟁 구도

제17장 전략적 제안

제18장 기업 소개 및 면책사항